Arexvy is indicated for active immunisation for the prevention of LRTD caused by respiratory syncytial virus in: adults 60 years of age and older; adults 50 through 59 years of age who are at increased risk for RSV disease.
The use of this vaccine should be in accordance with official recommendations.
Other Services
Country
Account